Condition (MeSH)
Mutism
ClinicalTrials.gov lists 18 trials for Mutism or a narrower condition beneath it. National Healthcare Group, Singapore has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 18 trials are tagged with Mutism itself; the rest are tagged with a narrower condition beneath it.
When did Mutism trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 3 |
| 2015 | 1 |
| 2014 | 3 |
| 2011 | 1 |
| 2009 | 1 |
| 2007 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mutism trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Not applicable | 11 |
| Observational | 3 |
How many Mutism trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 14 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mutism trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Healthcare Group, Singapore | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Prozac Pulvules 40 mg | 2 |
| Treatment As Usual | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Mutism? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours: a prospective, multicentre study. | Acta neurochirurgica | 2025 | Yes |
| Emotion regulation in selective mutism: A comparison group study in children and adolescents with selective mutism. | Journal of psychiatric research | 2022 | Yes |
| Arterial Spin-Labeling Perfusion Metrics in Pediatric Posterior Fossa Tumor Surgery. | AJNR. American journal of neuroradiology | 2022 | Yes |
| Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. | Neuro-oncology | 2021 | Yes |
| Betrayed by the nervous system: a comparison group study to investigate the 'unsafe world' model of selective mutism. | Journal of neural transmission (Vienna, Austria : 1996) | 2021 | Yes |
Showing 5 of 19 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.